India, April 23 -- Cumberland Pharmaceuticals Inc. (CPIX), a U.S. specialty pharmaceutical company, has entered into an agreement to transfer its portfolio of branded prescription products to Apotex, a Canadian-based pharmaceutical company, in a transaction valued at $100 million in cash.
The deal will integrate Cumberland's U.S. commercial business into Apotex, creating a broader platform for distributing specialty medicines across the country. The transaction remains subject to authorization and approval by Cumberland's shareholders.
Cumberland will retain its development-stage pipeline, including Ifetroban, a thromboxane antagonist being evaluated across multiple Phase II programs. The company recently reported breakthrough results in ...